- Home
- EDSA vs KZIA Comparison
EDSA vs KZIA Comparison
Compare EDSA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- KZIA
- Stock Information
- Founded
- EDSA 2015
- KZIA 1994
- Country
- EDSA Canada
- KZIA Australia
- Employees
- EDSA N/A
- KZIA N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- KZIA Health Care
- Exchange
- EDSA Nasdaq
- KZIA Nasdaq
- Market Cap
- EDSA 6.2M
- KZIA 6.0M
- IPO Year
- EDSA N/A
- KZIA 1999
- Fundamental
- Price
- EDSA $2.26
- KZIA $3.30
- Analyst Decision
- EDSA Strong Buy
- KZIA Strong Buy
- Analyst Count
- EDSA 1
- KZIA 2
- Target Price
- EDSA $21.00
- KZIA $11.50
- AVG Volume (30 Days)
- EDSA 11.4K
- KZIA 66.1K
- Earning Date
- EDSA 05-09-2025
- KZIA 04-21-2025
- Dividend Yield
- EDSA N/A
- KZIA N/A
- EPS Growth
- EDSA N/A
- KZIA N/A
- EPS
- EDSA N/A
- KZIA N/A
- Revenue
- EDSA N/A
- KZIA $1,655,324.00
- Revenue This Year
- EDSA N/A
- KZIA N/A
- Revenue Next Year
- EDSA N/A
- KZIA N/A
- P/E Ratio
- EDSA N/A
- KZIA N/A
- Revenue Growth
- EDSA N/A
- KZIA 248000.00
- 52 Week Low
- EDSA $1.55
- KZIA $2.86
- 52 Week High
- EDSA $5.59
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- EDSA 46.91
- KZIA 33.36
- Support Level
- EDSA $2.11
- KZIA $3.30
- Resistance Level
- EDSA $2.34
- KZIA $3.95
- Average True Range (ATR)
- EDSA 0.13
- KZIA 0.47
- MACD
- EDSA -0.01
- KZIA 0.01
- Stochastic Oscillator
- EDSA 40.45
- KZIA 27.41
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.